# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.
HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.
Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate o...
HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price t...
Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.
Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(65.90) per share which missed the analyst consensus estimate ...